Invirsa Inc. is a clinical-stage pharmaceutical company focused on developing an innovative topically administered eyedrop formulation, INV-102 for ocular conditions associated with DNA damage. Invirsa’s lead compound (INV-102), quickly and predictably augments the body’s response to DNA damage, greatly improving cell stability at the critical moment.

Industry Sector
Biomedical & Health Tech

Founded
2014

JumpStart Investment
Evergreen Fund III